Are You Missing Mold Illness In Your Patients?

---

Mold Intensive Course For Medical Practitioners

---

Release Date: 9/10/2025 
Expiration Date: 12/31/2026 

---

Activity Overview
This activity introduces clinicians to the fundamental science and clinical recognition of mold and mycotoxin illness. Topics include immune suppression and mast cell activation, specific mechanisms of common mycotoxins, strengths and limitations of current laboratory assessments, and the application of a therapeutic order to guide individualized treatment. Participants will gain a structured foundation to identify, assess, and manage patients affected by toxic mold exposure.

---

Target Audience
This activity is designed for an audience of physicians, nurses, psychologists, and other healthcare professionals interested in recognizing, assessing, and treating mold and mycotoxin-related illness.

---

Learning Objectives

Immune Impacts of Mold Spores and Spore Fragments
Upon completion of the educational activity, participants should be able to:

• Describe the mechanisms by which mold and mycotoxin exposure impact immune function.
• Analyze specific patterns of immune depletion with common symptom presentations in mold-related illness.
• Identify potential therapeutic targets based on the type and extent of immune impairment observed.

Mold Mycotoxins and Specific Mechanisms
Upon completion of the educational activity, participants should be able to:

• Explain the mechanisms of action of mycotoxins associated with water-damaged buildings.
• Differentiate the structural and biosynthetic diversity among common mycotoxins and the implications for health effects.
• Compare variations in mycotoxin mechanisms to the diversity of symptom patterns among patients.

Mold and Mycotoxin Assessment
Upon completion of the educational activity, participants should be able to:

• Apply a clinical questionnaire and targeted physical exam to improve identification of mold-related illness.
• Select appropriate testing methods based on patient presentation and available laboratory options.
• Implement strategies to overcome known limitations of current mold and mycotoxin assessment tools.

Treatment of Mold and Mycotoxins
Upon completion of the educational activity, participants should be able to:

• Outline a therapeutic order for the treatment of toxic indoor mold exposure.
• Incorporate mold and mycotoxin avoidance strategies into patient care, including environmental, dietary, and supplement considerations.
• Evaluate the rationale for both systemic and intranasal antifungal therapies in mold-related illness.
• Apply strategies to protect the microbiome, detoxification organs, and immune system during treatment.
• Discuss the role of biofilm in chronic illness and recovery.

---

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate.  You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at lritley@akhcme.com.

---

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 10.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Credit being awarded: 10.0 ANCC contact hours.

Psychologists

---

Commercial Support
There is no commercial support for this activity.

---

DISCLOSURES
Name	Relationship	Commercial Interest
Jill Crista, ND	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN – President, AKH Inc., Advancing Knowledge in Healthcare	N/A	Nothing to disclose
Jennifer Kasey, Psy.D.	N/A	Nothing to disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to disclose
AKH Inc Staff and Planners	N/A	Nothing to disclose
Crista Corporation Staff and Planners	N/A	Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

---

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with “Opt Out” in the subject line.

---